{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:34:29Z","timestamp":1762544069320,"version":"3.37.3"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013172","name":"SymBio Pharmaceuticals Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Adult T-cell leukemia\/lymphoma (ATL) develops from the infection of T cells with human T lymphotropic virus type 1 (HTLV-1). There are an estimated 5\u201320 million HTLV-1 carriers worldwide and the patients are frequently observed in subtropical Africa, the Caribbean, Middle East, South America, and South West Japan. The prognosis of ATL remains dismal due to rapid acquired resistance to treatment with cytotoxic chemotherapeutic agents. In particular, the development of novel therapies for relapsed or refractory (R\/R) ATL is an unmet need. Previous clinical trials revealed that bendamustine (BDM) was effective as the first-line treatment for indolent lymphoma and R\/R cases of diffuse large B-cell lymphoma. Its major advantage is that it has few side effects such as hair loss and peripheral neuropathy, and does not impair the quality of life. However, its efficacy has not been verified for ATL in pre-clinical or clinical studies. In this study, we have shown the cytotoxicity of BDM alone and in combination with novel agents including the histone deacetylase (HDAC) inhibitor tucidinostat, the enhancer of zeste homolog 1\/2 (EZH1\/2) dual inhibitor valemetostat, and the Bcl2 family inhibitor ABT-737. The combined <jats:italic>in vitro<\/jats:italic> effects of BDM and tucidinostat were reproduced in a murine model without any obvious hematological toxicity. Our present results suggest that the combination of tucidinostat and BDM could additively prolong the survival of patients with R\/R progressive ATL. The efficacy and safety of this combination are thus worthy of investigation in clinical settings.<\/jats:p>","DOI":"10.1371\/journal.pone.0309533","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:29:28Z","timestamp":1727717368000},"page":"e0309533","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells"],"prefix":"10.1371","volume":"19","author":[{"given":"Naoki","family":"Osada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8791-3263","authenticated-orcid":true,"given":"Jiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"pone.0309533.ref001","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases","volume":"24","author":"FA Proietti","year":"2005","journal-title":"Oncogene"},{"key":"pone.0309533.ref002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"M Iwanaga","year":"2012","journal-title":"Front Microbiol"},{"key":"pone.0309533.ref003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12185-023-03572-4","article-title":"Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma.","volume":"117","author":"H Katsuya","year":"2023","journal-title":"Int J Hematol"},{"key":"pone.0309533.ref004","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"K Kataoka","year":"2015","journal-title":"Nat Genet"},{"key":"pone.0309533.ref005","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0005-2787(72)90282-1","article-title":"Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943","volume":"287","author":"M Hartmann","year":"1972","journal-title":"Biochim Biophys Acta"},{"key":"pone.0309533.ref006","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.","volume":"14","author":"LM Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"pone.0309533.ref007","doi-asserted-by":"crossref","first-page":"e90675","DOI":"10.1371\/journal.pone.0090675","article-title":"Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies","volume":"9","author":"N Hiraoka","year":"2014","journal-title":"PLoS One"},{"key":"pone.0309533.ref008","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/or.2022.8325","article-title":"Bendamustine: A review of pharmacology, clinical use and immunological effects","volume":"47","author":"H Lalic","year":"2022","journal-title":"Oncol Rep"},{"key":"pone.0309533.ref009","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bjh.15722","article-title":"Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis","volume":"184","author":"M Martinez-Calle","year":"2019","journal-title":"Br J Haematol"},{"key":"pone.0309533.ref010","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","article-title":"Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results.","volume":"113","author":"A Utsunomiya","year":"2022","journal-title":"Cancer Sci"},{"key":"pone.0309533.ref011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","article-title":"Mechanisms of action and resistance in histone methylation-targeted therapy","volume":"627","author":"M Yamagishi","year":"2024","journal-title":"Nature"},{"key":"pone.0309533.ref012","first-page":"5287","article-title":"Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia\/lymphoma","volume":"34","author":"N Kunami","year":"2014","journal-title":"Anticancer Res"},{"key":"pone.0309533.ref013","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.4049\/jimmunol.135.6.3995","article-title":"TCGF (IL2)-receptor induction factor(s). II. Possible role of ATL-derived factor (ADF) on constitutive IL2 receptor expression of HTLV-1(+) T cell lines","volume":"135","author":"M Okada","year":"1985","journal-title":"J Immunol"},{"key":"pone.0309533.ref014","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/10428199609093442","article-title":"Features of the cytokines secreted by adult T cell leukemia (ATL) cells.","volume":"21","author":"Y Yamada","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"pone.0309533.ref015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0165-4608(88)90171-9","article-title":"Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells","volume":"34","author":"T Naoe","year":"1988","journal-title":"Cancer Genet Cytogenet"},{"key":"pone.0309533.ref016","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease","volume":"79","author":"M Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"pone.0309533.ref017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.2910340213","article-title":"Cell surface phenotypes and expression of viral antigens of various human cell lines carrying human T-cell leukemia virus","volume":"34","author":"K Sugamura","year":"1984","journal-title":"Int J Cancer"},{"key":"pone.0309533.ref018","doi-asserted-by":"crossref","first-page":"e1364","DOI":"10.1002\/ctm2.1364","article-title":"c-FOS mediates IMiDs resistance acting as a co-activator of IKZF1-target genes in multiple myeloma","volume":"13","author":"N Osada","year":"2023","journal-title":"Clin Transl Med"},{"key":"pone.0309533.ref019","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3324\/haematol.2021.278506","article-title":"mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation","volume":"106","author":"N Osada","year":"2021","journal-title":"Haematologica"},{"key":"pone.0309533.ref020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"TC Chou","year":"2010","journal-title":"Cancer Res"},{"key":"pone.0309533.ref021","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bbmt.2020.04.006","article-title":"Development of a unique T cell receptor gene-transferred Tax-redirected T cell immunotherapy for adult T cell leukemia","volume":"26","author":"K Kawamura","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"pone.0309533.ref022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: new targets and novel therapies","volume":"11","author":"BD Cheson","year":"2021","journal-title":"Blood Cancer J"},{"key":"pone.0309533.ref023","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ejh.12609","article-title":"Bendamustine in multiple myeloma","volume":"95","author":"M Gentile","year":"2015","journal-title":"Eur J Haematol"},{"key":"pone.0309533.ref024","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1038\/bcj.2013.66","article-title":"Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma","volume":"3","author":"N Hiraoka","year":"2013","journal-title":"Blood Cancer J"},{"key":"pone.0309533.ref025","doi-asserted-by":"crossref","first-page":"932914","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Y Sun","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:29:34Z","timestamp":1727717374000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309533"}},"subtitle":[],"editor":[{"given":"Elisabetta","family":"Pilotti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309533","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}